Subject category:
Strategy and General Management
Published by:
International Institute for Management Development (IMD)
Version: 11.02.2005
Length: 2 pages
Data source: Published sources
Abstract
This is the second of a four-case series (IMD-3-1496 to IMD-3-1499). The (B) part of the series focuses on the outcome of the lawsuit against the South African government. But the demands from the non-government organisations (NGO''s) keep on coming and Garnier, the CEO of GlaxoSmithKline (GSK), is faced with some tough decisions to make. Should he allow licensing? How should he deal with parallel importation?
Location:
Industry:
Size:
Largest pharmaceutical company in the world, more than 100,000 employees
Other setting(s):
2001-2004
About
Abstract
This is the second of a four-case series (IMD-3-1496 to IMD-3-1499). The (B) part of the series focuses on the outcome of the lawsuit against the South African government. But the demands from the non-government organisations (NGO''s) keep on coming and Garnier, the CEO of GlaxoSmithKline (GSK), is faced with some tough decisions to make. Should he allow licensing? How should he deal with parallel importation?
Settings
Location:
Industry:
Size:
Largest pharmaceutical company in the world, more than 100,000 employees
Other setting(s):
2001-2004